Paul J Thornalley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1273311/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal, 1999, 344, 109-116.	3.7	1,031
2	Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. BBA - Proteins and Proteomics, 1985, 827, 36-44.	2.1	936
3	Unraveling the Biological Roles of Reactive Oxygen Species. Cell Metabolism, 2011, 13, 361-366.	16.2	661
4	Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Critical Care Medicine, 2009, 37, 1355-1364.	0.9	593
5	Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochemical Journal, 2003, 375, 581-592.	3.7	580
6	Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics, 2003, 419, 31-40.	3.0	553
7	Glyoxalase I – structure, function and a critical role in the enzymatic defence against glycation. Biochemical Society Transactions, 2003, 31, 1343-1348.	3.4	547
8	Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. General Pharmacology, 1996, 27, 565-573.	0.7	533
9	Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications. Clinical Science, 1994, 87, 21-29.	4.3	512
10	The formation of methylglyoxal from triose phosphates. FEBS Journal, 1993, 212, 101-105.	0.2	477
11	The glyoxalase system in health and disease. Molecular Aspects of Medicine, 1993, 14, 287-371.	6.4	471
12	Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis Journal of Clinical Investigation, 1998, 101, 1142-1147.	8.2	441
13	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine, 2012, 18, 926-933.	30.7	414
14	PROTEIN AND NUCLEOTIDE DAMAGE BY GLYOXAL AND METHYLGLYOXAL IN PHYSIOLOGICAL SYSTEMS - ROLE IN AGEING AND DISEASE. Drug Metabolism and Drug Interactions, 2008, 23, 125-150.	0.3	375
15	Dicarbonyl Intermediates in the Maillard Reaction. Annals of the New York Academy of Sciences, 2005, 1043, 111-117.	3.8	357
16	Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nature Metabolism, 2022, 4, 651-662.	11.9	356
17	Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotiamine. Diabetes, 2003, 52, 2110-2120.	0.6	348
18	Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids, 2012, 42, 1133-1142.	2.7	345

#	Article	IF	CITATIONS
19	Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal, 1999, 344, 109.	3.7	325
20	Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes, Obesity and Metabolism, 2007, 9, 233-245.	4.4	316
21	Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nâ°Š-carboxymethyl-lysine- and Nâ°Š-(1-carboxyethyl)lysine-modified albumin. Biochemical Journal, 2002, 364, 1-14	3.7	307
22	Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chemico-Biological Interactions, 1998, 111-112, 137-151.	4.0	269
23	Peptide Mapping Identifies Hotspot Site of Modification in Human Serum Albumin by Methylglyoxal Involved in Ligand Binding and Esterase Activity. Journal of Biological Chemistry, 2005, 280, 5724-5732.	3.4	269
24	Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochemical and Biophysical Research Communications, 2015, 458, 221-226.	2.1	269
25	Effect of storage, processing and cooking on glucosinolate content of Brassica vegetables. Food and Chemical Toxicology, 2007, 45, 216-224.	3.6	259
26	Glyoxalaseâ€1 prevents mitochondrial protein modification and enhances lifespan in <i> Caenorhabditis elegans</i> . Aging Cell, 2008, 7, 260-269.	6.7	251
27	Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochemical Journal, 2012, 443, 213-222.	3.7	251
28	Methylglyoxal-Derived Hydroimidazolone Advanced Glycation End-Products of Human Lens Proteins. , 2003, 44, 5287.		250
29	<i>C. elegans</i> as Model for the Study of High Glucose– Mediated Life Span Reduction. Diabetes, 2009, 58, 2450-2456.	0.6	248
30	Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney International, 2018, 93, 803-813.	5.2	239
31	Increased Dicarbonyl Metabolism in Endothelial Cells in Hyperglycemia Induces Anoikis and Impairs Angiogenesis by RGD and GFOGER Motif Modification. Diabetes, 2006, 55, 1961-1969.	0.6	234
32	Accumulation of α-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochemical Pharmacology, 1999, 58, 641-648.	4.4	225
33	High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50, 2164-2170.	6.3	223
34	The assay of methylglyoxal in biological systems byderivatization with 1,2-diamino-4,5-dimethoxybenzene. Analytical Biochemistry, 1992, 206, 17-23.	2.4	220
35	Activation of NF-E2–Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease. Diabetes, 2008, 57, 2809-2817.	0.6	214
36	Stimulation of Suicidal Erythrocyte Death by Methylglyoxal. Cellular Physiology and Biochemistry, 2006, 18, 223-232.	1.6	212

#	Article	IF	CITATIONS
37	Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia, 2005, 48, 1590-1603.	6.3	211
38	Glyoxalase in diabetes, obesity and related disorders. Seminars in Cell and Developmental Biology, 2011, 22, 309-317.	5.0	205
39	Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. The Protein Journal, 1995, 14, 359-372.	1.1	200
40	Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. Journal of Neurochemistry, 2005, 92, 255-263.	3.9	199
41	Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nature Protocols, 2014, 9, 1969-1979.	12.0	198
42	High Glucose Increases Angiopoietin-2 Transcription in Microvascular Endothelial Cells through Methylglyoxal Modification of mSin3A. Journal of Biological Chemistry, 2007, 282, 31038-31045.	3.4	195
43	Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochemical Pharmacology, 2000, 60, 55-65.	4.4	190
44	Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. International Review of Neurobiology, 2002, 50, 37-57.	2.0	187
45	Transcription Factor Nrf2 Is Essential for Induction of NAD(P)H:Quinone Oxidoreductase 1, Glutathione S-Transferases, and Glutamate Cysteine Ligase by Broccoli Seeds and Isothiocyanates. Journal of Nutrition, 2004, 134, 3499S-3506S.	2.9	181
46	Involvement of a gut–retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4472-E4481.	7.1	179
47	Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis. Leukemia Research, 1996, 20, 397-405.	0.8	175
48	Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes, 2016, 65, 2282-2294.	0.6	170
49	Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2003, 52, 163-167.	3.4	160
50	Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes. Diabetes, 2009, 58, 2893-2903.	0.6	155
51	Glyoxalase in ageing. Seminars in Cell and Developmental Biology, 2011, 22, 293-301.	5.0	154
52	Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Biochemical Pharmacology, 1996, 51, 1365-1372.	4.4	151
53	Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochemical Society Transactions, 2008, 36, 1045-1050.	3.4	149
54	Studies on the mechanism of the inhibition of human leukaemia cell growth by dietary isothiocyanates and their cysteine adducts in vitro. Biochemical Pharmacology, 2000, 60, 221-231.	4.4	145

#	Article	IF	CITATIONS
55	High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia, 2009, 52, 208-212.	6.3	145
56	Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochemical Journal, 2002, 364, 15-24.	3.7	143
57	Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochemical Society Transactions, 2003, 31, 1417-1422.	3.4	142
58	Glyoxalase in tumourigenesis and multidrug resistance. Seminars in Cell and Developmental Biology, 2011, 22, 318-325.	5.0	142
59	The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications. Current Diabetes Reviews, 2005, 1, 287-298.	1.3	141
60	Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochemical Society Transactions, 2003, 31, 1423-1425.	3.4	140
61	Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity. Diabetes, 2011, 60, 1973-1980.	0.6	140
62	Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clinical Science, 2005, 109, 83-95.	4.3	139
63	Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Molecular Nutrition and Food Research, 2005, 49, 691-699.	3.3	137
64	Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Biochemical Pharmacology, 1993, 46, 805-811.	4.4	134
65	Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconjugate Journal, 2016, 33, 513-525.	2.7	130
66	Profound Mishandling of Protein Glycation Degradation Products in Uremia and Dialysis. Journal of the American Society of Nephrology: JASN, 2005, 16, 1471-1485.	6.1	128
67	Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments. Clinical Science, 2016, 130, 1677-1696.	4.3	124
68	Isothiocyanates: mechanism of cancer chemopreventive action. Anti-Cancer Drugs, 2002, 13, 331-338.	1.4	123
69	Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1639, 121-132.	3.8	121
70	Analysis of glucosinolates, isothiocyanates, and amine degradation products in vegetable extracts and blood plasma by LC–MS/MS. Analytical Biochemistry, 2005, 347, 234-243.	2.4	121
71	cysteine conjugate to human leukaemia cells in vitro11Abbreviations: BSÓ, l-buthionine sulphoximine; DNP-SG, S-2,4-dinitrophenylglutathione; DTT, dithiothreitol; GST, glutathione S-transferase; HL6O, human leukaemia 60; JNK1, c-Jun N-terminal kinase 1; ML-1, human myeloblastic leukaemia-1; PEITC, phenethyl isothiocyanate: PETC, N-phenethylthiocarbamoyl: PETC-Cys.	4.4	120
72	S-(N-phénethylthiocarbamoyl)cysteine: PETC-SG, S. Biochémical Pharmacology, 2001, 61, 165-177. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia, 2010, 53, 1506-1516.	6.3	120

#	Article	IF	CITATIONS
73	The Critical Role of Methylglyoxal and Glyoxalase 1 in Diabetic Nephropathy. Diabetes, 2014, 63, 50-52.	0.6	120
74	Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochemical Society Transactions, 2003, 31, 1372-1377.	3.4	118
75	Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes. Diabetes Care, 2005, 28, 2465-2471.	8.6	117
76	Detection of oxidized and glycated proteins in clinical samples using mass spectrometry — A user's perspective. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 818-829.	2.4	117
77	The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Research and Clinical Practice, 1989, 7, 115-120.	2.8	113
78	Glycation research in amino acids: a place to call home. Amino Acids, 2012, 42, 1087-1096.	2.7	113
79	Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochemical Society Transactions, 2014, 42, 425-432.	3.4	112
80	Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients With Type 2 Diabetes and Effect of Metformin. Diabetes, 2010, 59, 1038-1045.	0.6	109
81	Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, Nepsilon-(1-deoxy-d-fructos-1-yl)hippuryl-lysine. FEBS Journal, 1992, 210, 729-739.	0.2	108
82	The autoxidation of glyceraldehyde and other simple monosaccharides. Experientia, 1984, 40, 244-246.	1.2	102
83	Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-d-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Critical Reviews in Oncology/Hematology, 1995, 20, 99-128.	4.4	99
84	Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. Nucleic Acids Research, 2010, 38, 5432-5442.	14.5	98
85	Suppression of the Accumulation of Triosephosphates and Increased Formation of Methylglyoxal in Human Red Blood Cells during Hyperglycaemia by Thiamine In Vitro. Journal of Biochemistry, 2001, 129, 543-549.	1.7	96
86	<i>GLO1</i> —A novel amplified gene in human cancer. Genes Chromosomes and Cancer, 2010, 49, 711-725.	2.8	95
87	Phenyl radical production during the oxidation of phenylhydrazine and in phenylphydrazine-induced haemolysis. FEBS Letters, 1981, 125, 235-238.	2.8	93
88	Glyoxalase activity in human red blood cells fractioned by age. Mechanisms of Ageing and Development, 1989, 48, 63-71.	4.6	91
89	The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochemical Pharmacology, 1994, 48, 1865-1870.	4.4	90
90	Fluorimetric assay of d-lactate. Analytical Biochemistry, 1992, 206, 12-16.	2.4	89

6

#	Article	IF	CITATIONS
91	Measurement of glyoxalase activities. Biochemical Society Transactions, 2014, 42, 491-494.	3.4	88
92	Methylglyoxal Concentration and Glyoxalase Activities in the Human Lens. Experimental Eye Research, 1994, 59, 497-500.	2.6	86
93	High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia, 2004, 47, 2235-2246.	6.3	85
94	Synthesis and chromatography of 1,2-diamino-4,5-dimethoxybenzene, 6,7-dimethoxy-2-methylquinoxaline and 6,7-dimethoxy-2,3-dimethylquinoxaline for use in a liquid chromatographic fluorimetric assay of methylglyoxal. Analytica Chimica Acta, 1992, 263, 137-142.	5.4	84
95	Activity, regulation, copy number and function in the glyoxalase system. Biochemical Society Transactions, 2014, 42, 419-424.	3.4	83
96	Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood, 2013, 122, 134-142.	1.4	79
97	Signal transduction activated by the cancer chemopreventive isothiocyanates: cleavage of BID protein, tyrosine phosphorylation and activation of JNK. British Journal of Cancer, 2001, 84, 670-673.	6.4	78
98	<i>The Dicarbonyl Proteome</i> . Annals of the New York Academy of Sciences, 2008, 1126, 124-127.	3.8	75
99	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrology Dialysis Transplantation, 2007, 22, 3381-3390.	0.7	74
100	Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney International, 2007, 72, 1113-1121.	5.2	74
101	Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cellular and Molecular Life Sciences, 2011, 68, 721-733.	5.4	73
102	Mass spectrometric determination of early and advanced glycation in biology. Glycoconjugate Journal, 2016, 33, 553-568.	2.7	72
103	Inhibition of proliferation of human leukaemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochemical Pharmacology, 1992, 44, 2357-2363.	4.4	71
104	Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes, 1998, 47, 1960-1966.	0.6	71
105	Quantitative measurement of specific biomarkers for protein oxidation, nitration and glycation in Arabidopsis leaves. Plant Journal, 2009, 59, 661-671.	5.7	71
106	Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal. Scientific Reports, 2019, 9, 7889.	3.3	69
107	Assay of methylglyoxal-derived protein and nucleotide AGEs. Biochemical Society Transactions, 2014, 42, 511-517.	3.4	67
108	A mechanism for primaquine mediated oxidation of NADPH in red blood cells. Biochemical Pharmacology, 1983, 32, 3571-3575.	4.4	66

#	Article	IF	CITATIONS
109	Methylglyoxal, glyoxalases and the development of diabetic complications. Amino Acids, 1994, 6, 15-23.	2.7	66
110	Hyperglycemic kidney damage in an animal model of prolonged critical illness. Kidney International, 2009, 76, 512-520.	5.2	66
111	Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochemical Pharmacology, 1985, 34, 669-674.	4.4	64
112	Mass spectrometric monitoring of albumin in uremia. Kidney International, 2000, 58, 2228-2234.	5.2	64
113	Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. Antioxidants and Redox Signaling, 2015, 23, 613-629.	5.4	63
114	Peptide Mapping of Human Serum Albumin Modified Minimally by Methylglyoxalin Vitroandin Vivo. Annals of the New York Academy of Sciences, 2005, 1043, 260-266.	3.8	62
115	PROGRESS IN UREMIC TOXIN RESEARCH: Highlights and Hotspots of Protein Glycation in Endâ€Stage Renal Disease. Seminars in Dialysis, 2009, 22, 400-404.	1.3	62
116	Glyoxalase 1 Modulation in Obesity and Diabetes. Antioxidants and Redox Signaling, 2019, 30, 354-374.	5.4	62
117	Inhibition of proliferation of human promyelocytic leukaemia HL60 cells by S-d-lactoylglutathione in vitro. Leukemia Research, 1988, 12, 897-904.	0.8	61
118	Dicarbonyl stress in clinical obesity. Glycoconjugate Journal, 2016, 33, 581-589.	2.7	60
119	Antimalarial activity in vitro of the glyoxalase I inhibitor diester, S-p-bromobenzylglutathione diethyl ester. Biochemical Pharmacology, 1994, 47, 418-420.	4.4	59
120	Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. Journal of Hepatology, 2004, 41, 913-919.	3.7	59
121	Rapid hydrolysis and slow \hat{l}_{\pm}, \hat{l}^2 -dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochemical Pharmacology, 1999, 57, 303-307.	4.4	58
122	Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. Molecular Autism, 2018, 9, 3.	4.9	58
123	Multiple roles of glyoxalase 1-mediated suppression of methylglyoxal glycation in cancer biology—Involvement in tumour suppression, tumour growth, multidrug resistance and target for chemotherapy. Seminars in Cancer Biology, 2018, 49, 83-93.	9.6	58
124	The production of free radicals during the autoxidation of monosaccharides by buffer ions. Carbohydrate Research, 1984, 134, 191-204.	2.3	57
125	Induction of synthesis and secretion of interleukin 1Î ² in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunology Letters, 1996, 50, 17-21.	2.5	57
126	Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE) – an introduction. Molecular Nutrition and Food Research, 2007, 51, 1107-1110.	3.3	57

#	Article	IF	CITATIONS
127	Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutrition and Diabetes, 2014, 4, e134-e134.	3.2	57
128	Advanced Glycation End Products in Renal Failure. , 2006, 16, 178-184.		55
129	Protein oxidation, nitration and glycation biomarkers for early-stage diagnosis of osteoarthritis of the knee and typing and progression of arthritic disease. Arthritis Research and Therapy, 2016, 18, 250.	3.5	54
130	Aging-Dependent Reduction in Glyoxalase 1 Delays Wound Healing. Gerontology, 2013, 59, 427-437.	2.8	53
131	Hexokinase-2 Glycolytic Overload in Diabetes and Ischemia–Reperfusion Injury. Trends in Endocrinology and Metabolism, 2019, 30, 419-431.	7.1	53
132	Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes, Obesity and Metabolism, 2011, 13, 577-583.	4.4	52
133	Synthesis and secretion of tumour necrosis factor-α by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunology Letters, 1997, 58, 139-147.	2.5	51
134	The generation of hydroxyl radicals following superoxide production by neutrophil NADPH oxidase. FEBS Letters, 1982, 150, 300-302.	2.8	50
135	Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies. Biochemical Society Transactions, 1993, 21, 531-534.	3.4	50
136	Effects of Methylglyoxal on Rat Pancreatic β-Cells. Biochemical Pharmacology, 1998, 55, 1361-1367.	4.4	50
137	Glycation free adduct accumulation in renal disease: the new AGE. Pediatric Nephrology, 2005, 20, 1515-1522.	1.7	49
138	Formation of methylglyoxal and <scp>d</scp> -lactate in human red blood cells <i>in vitro</i> . Biochemical Society Transactions, 1993, 21, 163S-163S.	3.4	48
139	Highâ€Dose Thiamine Therapy Counters Dyslipidemia and Advanced Glycation of Plasma Protein in Streptozotocinâ€Induced Diabetic Rats. Annals of the New York Academy of Sciences, 2005, 1043, 777-783.	3.8	48
140	Endogenous α-Oxoaldehydes and Formation of Protein and Nucleotide Advanced Glycation Endproducts in Tissue Damage. Novartis Foundation Symposium, 2007, 285, 229-246.	1.1	48
141	NÂ-(Carboxymethyl)lysine and 3-DG-Imidazolone Are Major AGE Structures in Protein Modification by 3-Deoxyglucosone. Journal of Biochemistry, 2004, 136, 351-358.	1.7	47
142	Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health. Scientific Reports, 2015, 5, 9259.	3.3	47
143	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2012, 7, e35655.	2.5	46
144	A simplified method for the purification of human red blood cell glyoxalase. I. Characteristics, immunoblotting, and inhibitor studies. The Protein Journal, 1993, 12, 111-119.	1.1	45

#	Article	IF	CITATIONS
145	The production of hydroxyl radicals by adriamycin in red blood cells. FEBS Letters, 1983, 157, 170-172.	2.8	44
146	<i>Reversal of Hyperglycemiaâ€Induced Angiogenesis Deficit of Human Endothelial Cells by Overexpression of Glyoxalase 1</i> <scp>In Vitro</scp> . Annals of the New York Academy of Sciences, 2008, 1126, 262-264.	3.8	44
147	Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine. Redox Biology, 2021, 42, 101920.	9.0	44
148	Purification and characterisation of glyoxalase II from human red blood cells. FEBS Journal, 1993, 213, 1261-1267.	0.2	43
149	Antitumor Activity ofS-(p-Bromobenzyl)glutathione Diestersin Vitro:Â A Structureâ^'Activity Study. Journal of Medicinal Chemistry, 1996, 39, 3409-3411.	6.4	43
150	Glucose-Induced Down Regulation of Thiamine Transporters in the Kidney Proximal Tubular Epithelium Produces Thiamine Insufficiency in Diabetes. PLoS ONE, 2012, 7, e53175.	2.5	43
151	Glyoxalase activity during differentiation of human leukaemia cells in vitro. Leukemia Research, 1987, 11, 1141-1148.	0.8	42
152	Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. Trends in Molecular Medicine, 2006, 12, 195-199.	6.7	42
153	Benfotiamine Protects against Peritoneal and Kidney Damage in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2011, 22, 914-926.	6.1	42
154	Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Food and Chemical Toxicology, 1996, 34, 385-392.	3.6	39
155	Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunology Letters, 1996, 53, 7-13.	2.5	39
156	Glyoxalase 1-knockdown in human aortic endothelial cells – effect on the proteome and endothelial function estimates. Scientific Reports, 2016, 6, 37737.	3.3	39
157	The formation of active oxygen species following activation of 1-naphthol, 1,2- and 1,4-naphthoquinone by rat liver microsomes. Chemico-Biological Interactions, 1984, 48, 195-206.	4.0	38
158	Induction of TNFα and IL-1β mRNA in monocytes by methylglyoxal- and advanced glycated endproduct-modified human serum albumin. Biochemical Society Transactions, 1997, 25, 250S-250S.	3.4	38
159	Purification of major glucosinolates fromBrassicaceae seeds and preparation of isothiocyanate and amine metabolites. Journal of the Science of Food and Agriculture, 2006, 86, 1271-1280.	3.5	38
160	The Assay of S-D-Lactoylglutathione in Biological Systems. Analytical Biochemistry, 1993, 211, 37-43.	2.4	37
161	Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy. Journal of Diabetes Research, 2015, 2015, 1-10.	2.3	37
162	Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients, 2021, 13, 2374.	4.1	37

#	Article	IF	CITATIONS
163	Inhibition of proliferation of human leukaemia 60 cells by methylglyoxal in vitro. Leukemia Research, 1993, 17, 397-401.	0.8	36
164	Glyoxalase II does not support methylglyoxal detoxification but serves as a general trypanothione thioesterase in African trypanosomes. Molecular and Biochemical Parasitology, 2009, 163, 19-27.	1.1	36
165	Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiological Reports, 2014, 2, e12043.	1.7	35
166	Possible role of methylglyoxal and glyoxalase in arthritis. Biochemical Society Transactions, 2014, 42, 538-542.	3.4	35
167	The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. Kidney International, 2016, 90, 396-403.	5.2	35
168	Free radical production during phenylhydrazine-induced hemolysis. Canadian Journal of Chemistry, 1982, 60, 1528-1531.	1.1	34
169	The production of oxygen-centered radicals by Bacillus-Calmette-Guerin-activated macrophages. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 763, 245-250.	4.1	32
170	Protein damage in diabetes and uremia—identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radical Research, 2011, 45, 89-100.	3.3	32
171	Dicarbonyl stress, protein glycation and the unfolded protein response. Glycoconjugate Journal, 2021, 38, 331-340.	2.7	32
172	Formation of Methylglyoxal-Modified Proteins in vitro and in vivo and Their Involvement in AGE-Related Processes. Contributions To Nephrology, 1995, 112, 24-31.	1.1	31
173	Glyoxalase Centennial conference: introduction, history of research on the glyoxalase system and future prospects. Biochemical Society Transactions, 2014, 42, 413-418.	3.4	31
174	The reaction of superoxide radicals with metal picolinate complexes. Inorganica Chimica Acta, 1983, 78, 139-142.	2.4	30
175	S-D-lactoylglutathione in resting and activated human neutrophils. Biochemical and Biophysical Research Communications, 1987, 145, 769-774.	2.1	30
176	Modification of the glyoxalase system in human HL60 promyelocytic leukemia cells during differentiation to neutrophils in vitro. Biochimica Et Biophysica Acta - General Subjects, 1988, 966, 362-369.	2.4	30
177	Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochemical Society Transactions, 2003, 31, 1394-1396.	3.4	30
178	Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls. Free Radical Research, 2016, 50, S85-S90.	3.3	30
179	Binding of methylglyoxal to albumin and formation of fluorescent adducts. Inhibition by arginine, Nα-acetylarginine and aminoguanidine. Biochemical Society Transactions, 1993, 21, 170S-170S.	3.4	29
180	An EPR study of the production of superoxide radicals by neutrophil NADPH oxidase. FEBS Letters, 1982, 145, 323-326.	2.8	28

#	Article	IF	CITATIONS
181	Assay of 3â€Nitrotyrosine in Tissues and Body Fluids by Liquid Chromatography with Tandem Mass Spectrometric Detection. Methods in Enzymology, 2008, 440, 337-359.	1.0	28
182	The haemolytic reactions of 1-acetyl-2-phenylhydrazine and hydrazine: A spin trapping study. Chemico-Biological Interactions, 1984, 50, 339-349.	4.0	27
183	Evidence against the formation of 2-amino-6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid ('pyrraline') as an early-stage product or advanced glycation end product in non-enzymic protein glycation. Clinical Science, 1993, 84, 87-93.	4.3	27
184	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. Seminars in Dialysis, 2009, 22, 323-328.	1.3	27
185	Studies of advanced glycation end products and oxidation biomarkers for type 2 diabetes. BioFactors, 2018, 44, 281-288.	5.4	27
186	Sulforaphane Delays Fibroblast Senescence by Curbing Cellular Glucose Uptake, Increased Glycolysis, and Oxidative Damage. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	27
187	Inhibitors of glyoxalase I: Design, synthesis, inhibitory characteristics and biological evaluation. Biochemical Society Transactions, 1993, 21, 535-540.	3.4	26
188	Reappraisal of putative glyoxalase 1-deficient mouse and dicarbonyl stress on embryonic stem cells <i>in vitro</i> . Biochemical Journal, 2016, 473, 4255-4270.	3.7	26
189	Population genetics of human glyoxalases. Heredity, 1991, 67, 139-142.	2.6	25
190	Comparison of the delivery of reduced glutathione into P388D1 cells by reduced glutathione and its mono- and diethyl ester derivatives. Biochemical Pharmacology, 1995, 49, 1475-1482.	4.4	25
191	Increased Protein Glycation in Cirrhosis and Therapeutic Strategies to Prevent It. Annals of the New York Academy of Sciences, 2005, 1043, 718-724.	3.8	25
192	Advanced Glycation End Product Free Adducts Are Cleared by Dialysis. Annals of the New York Academy of Sciences, 2005, 1043, 734-739.	3.8	25
193	Assay of methylglyoxal and glyoxal and control of peroxidase interference. Biochemical Society Transactions, 2014, 42, 504-510.	3.4	24
194	Kinetics and mechanism of the reaction of metformin with methylglyoxal. International Congress Series, 2002, 1245, 355-356.	0.2	23
195	Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia—Link to renal status, glycemic control and vascular inflammation. Diabetes Research and Clinical Practice, 2012, 95, 415-424.	2.8	23
196	Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts. International Journal of Molecular Sciences, 2017, 18, 480.	4.1	23
197	Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity—Opportunity for Repurposed Chemotherapy of COVID-19 Infection. Frontiers in Pharmacology, 2020, 11, 585408.	3.5	23
198	Protein Glycation in Plants—An Under-Researched Field with Much Still to Discover. International Journal of Molecular Sciences, 2020, 21, 3942.	4.1	23

#	Article	IF	CITATIONS
199	A low glycemic diet protects disease-prone Nrf2-deficient mice against age-related macular degeneration. Free Radical Biology and Medicine, 2020, 150, 75-86.	2.9	23
200	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids, 2012, 42, 1627-1639.	2.7	22
201	Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysis—Driver of Insulin Resistance and Development of Vascular Complications of Diabetes. International Journal of Molecular Sciences, 2022, 23, 2165.	4.1	22
202	S-2-hydroxyacylglutathione-derivatives: enzymatic preparation, purification and characterisation. Journal of the Chemical Society Perkin Transactions 1, 1991, , 3009.	0.9	21
203	A fluorogenic assay for methylglyoxal. Biochemical Society Transactions, 2014, 42, 548-555.	3.4	21
204	Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. Proteome Science, 2018, 16, 4.	1.7	20
205	Vitamin B6, B9 and B12 in diabetic nephropathy—beware. Nature Reviews Endocrinology, 2010, 6, 477-478.	9.6	19
206	Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer. BMJ Open Diabetes Research and Care, 2020, 8, e001458.	2.8	19
207	Reading patterns of proteome damage by glycation, oxidation and nitration: quantitation by stable isotopic dilution analysis LC-MS/MS. Essays in Biochemistry, 2020, 64, 169-183.	4.7	19
208	Synthesis of 14C-labelled methylglyoxal and S-D-lactoylglutathione. Journal of Labelled Compounds and Radiopharmaceuticals, 1990, 28, 1455-1464.	1.0	18
209	Inhibition of human leukaemia 60 cell growth by S-d-lactoylglutathione in vitro. Mediation by metabolism to N-d-lactoylcysteine and induction of apoptosis. Leukemia Research, 1996, 20, 17-26.	0.8	18
210	Peptide Mapping of Human Hemoglobin Modified Minimally by Methylglyoxalin Vitro. Annals of the New York Academy of Sciences, 2005, 1043, 905-905.	3.8	18
211	Quantitation of Markers of Protein Damage by Glycation, Oxidation, and Nitration in Peritoneal Dialysis. Peritoneal Dialysis International, 2009, 29, 51-56.	2.3	18
212	Copy number variation of glyoxalase I. Biochemical Society Transactions, 2014, 42, 500-503.	3.4	18
213	Urinary Metabolomic Markers of Protein Glycation, Oxidation, and Nitration in Early-Stage Decline in Metabolic, Vascular, and Renal Health. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	4.0	18
214	Emerging Glycation-Based Therapeutics—Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 2453.	4.1	18
215	Reduction of Oxygen by NADH/NADH Dehydrogenase in the Presence of adriamycin. Free Radical Research Communications, 1986, 2, 163-171.	1.8	17
216	Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes. Diabetes, 2015, 64, 9-11.	0.6	17

#	Article	IF	CITATIONS
217	Quantitative Screening of Protein Glycation, Oxidation, and Nitration Adducts by LC-MS/MS: Protein Damage in Diabetes, Uremia, Cirrhosis, and Alzheimer's Disease. , 2006, , 681-727.		16
218	Measurement of protein glycation, glycated peptides, and glycation free adducts. Peritoneal Dialysis International, 2005, 25, 522-33.	2.3	16
219	Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathiones and monoethyl ester derivatives. Biochemical Pharmacology, 1992, 44, 1953-1959.	4.4	15
220	Frequency modulated translocational oscillations of Nrf2, a transcription factor functioning like a wireless sensor. Biochemical Society Transactions, 2015, 43, 669-673.	3.4	15
221	Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. Arthritis Research and Therapy, 2018, 20, 131.	3.5	15
222	Estimation of α-oxoaldehydes formed from the degradation of glycolytic intermediates and glucose fragmentation in blood plasma of human subjects with uraemia. International Congress Series, 2002, 1245, 181-182.	0.2	14
223	Novel anti-glycation therapeutic agents: glyoxalase I mimetics. International Congress Series, 2002, 1245, 107-111.	0.2	13
224	Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-d-lactoylglutathione in vitro. Leukemia Research, 1993, 17, 305-310.	0.8	12
225	Modification of the glyoxalase system in clinical diabetes mellitus. Biochemical Society Transactions, 1993, 21, 158S-158S.	3.4	12
226	Dietary and Synthetic Activators of the Antistress Gene Response in Treatment of Renal Disease. , 2012, 22, 195-202.		12
227	The potentiation of GTP-dependent assenbly of microtubules by S-D-lactoylglutathione. Biochemical Society Transactions, 1993, 21, 160S-160S.	3.4	11
228	The glyoxalase system—From microbial metabolism, through ageing to human disease and multidrug resistance. Seminars in Cell and Developmental Biology, 2011, 22, 261.	5.0	11
229	Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke. International Journal of Molecular Sciences, 2022, 23, 3387.	4.1	11
230	The effect of S-D-lactoylglutathione on the movement of neutrophils. Biochemical Society Transactions, 1993, 21, 161S-161S.	3.4	10
231	Antitumour activity of sphingoid base adducts of phenethyl isothiocyanate. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 53-54.	2.2	10
232	Determination of Types and Binding Sites of Advanced Glycation End Products for Substance P. Analytical Chemistry, 2012, 84, 10568-10575.	6.5	10
233	Measurement of glyoxalase gene expression. Biochemical Society Transactions, 2014, 42, 495-499.	3.4	10
234	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. Scientific Reports, 2020, 10, 12709.	3.3	10

#	Article	IF	CITATIONS
235	Potential Markers of Dietary Glycemic Exposures for Sustained Dietary Interventions in Populations without Diabetes. Advances in Nutrition, 2020, 11, 1221-1236.	6.4	10
236	Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome. Frontiers in Oncology, 2021, 11, 748698.	2.8	10
237	Study of an Unusual Advanced Glycation End-Product (AGE) Derived from Glyoxal Using Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2014, 25, 673-683.	2.8	9
238	Optimisation of non-denaturing polyacrylamide gel electrophoretic analysis of glyoxalase I phenotypes in clinical blood samples. Clinica Chimica Acta, 1991, 204, 137-143.	1.1	8
239	The hydrolysis of S-D-lactoylglutathione. Biochemical Society Transactions, 1993, 21, 169S-169S.	3.4	8
240	Discussion. Biochemical Pharmacology, 1999, 57, 583-588.	4.4	8
241	Human serum albumin minimally modified by methylglyoxal binds to human mononuclear leukocytes via the RAGE receptor and is displaced by Nîµ-carboxymethyl-lysine and hydroimidazolone AGE epitopes. International Congress Series, 2002, 1245, 77-81.	0.2	8
242	Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diabetes and Vascular Disease Research, 2004, 1, 21-22.	2.0	8
243	Are brain and heart tissue prone to the development of thiamine deficiency?. Alcohol, 2013, 47, 215-221.	1.7	8
244	Oxygen restriction as challenge test reveals early high-fat-diet-induced changes in glucose and lipid metabolism. Pflugers Archiv European Journal of Physiology, 2015, 467, 1179-1193.	2.8	8
245	Relation of the protein glycation, oxidation and nitration to the osteocalcin level in obese subjects. Acta Biochimica Polonica, 2017, 64, 415-422.	0.5	8
246	Red blood cell oxidative metabolism induced by hydroxypyruvaldehyde. Biochemical Pharmacology, 1985, 34, 1157-1164.	4.4	7
247	Glyoxalase activity in human tumour cell lines <i>in vitro</i> . Biochemical Society Transactions, 1993, 21, 167S-167S.	3.4	7
248	Prevention of S-d-lactoylglutathione-induced inhibition of human leukaemia 60 cell growth by uridine. Leukemia Research, 1994, 18, 717-722.	0.8	7
249	Reduced glutathione esters—antidotes to toxicity. Cytotoxicity induced by hydrogen peroxide, 1-chloro-2,4-dinitrobenzene, and menadione in murine P388D1 macrophages in vitro. Journal of Biochemical Toxicology, 1995, 10, 245-250.	0.4	7
250	Idiopathic hypoalbuminemia explained by reduced synthesis rate and an increased catabolic rate. Clinical Biochemistry, 2002, 35, 545-553.	1.9	7
251	Methylglyoxal Modification of mSin3A Links Glycolysis to Angiopoietin-2 Transcription. Cell, 2007, 128, 625.	28.9	7
252	Preparation of Nucleotide Advanced Glycation Endproducts-Imidazopurinone Adducts Formed by Glycation of Deoxyguanosine with Glyoxal and Methylglyoxal. Annals of the New York Academy of Sciences, 2008, 1126, 280-282.	3.8	7

#	Article	IF	CITATIONS
253	Dicarbonyl stress and the glyoxalase system. , 2020, , 759-777.		7
254	Modification of the glyoxalase system in streptozotocin-Induced diabetic rats and the effect of the aldose reductase Inhibitor Statil. Biochemical Society Transactions, 1993, 21, 162S-162S.	3.4	6
255	Thiamine in diabetic nephropathy: a novel treatment modality? Reply to Alkhalaf A, Kleefstra N, Groenier KH et al. [letter]. Diabetologia, 2009, 52, 1214-1216.	6.3	6
256	Î ³ -L-Glutamyl-O-acyl-L-serylglycine derivatives: synthesis, purification and evaluation as inhibitors of glyoxalases. Journal of the Chemical Society Perkin Transactions 1, 1992, , 639-643.	0.9	5
257	Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). Oncotarget, 2017, 8, 76961-76973.	1.8	5
258	Preparation and characterisation of NΪμ-(1-deoxy-d-fructos-1-yl)hippuryl-lysine. Carbohydrate Research, 1992, 223, 293-298.	2.3	4
259	Peptide Mapping of Type IV Collagen Modified Minimally by Methylglyoxalin Vitro. Annals of the New York Academy of Sciences, 2005, 1043, 906-906.	3.8	4
260	Inhibition of proliferation of human leukaemia 60 cells by methylglyoxal <i>in vitro</i> . Biochemical Society Transactions, 1993, 21, 168S-168S.	3.4	3
261	Reaction kinetics of the scavenging of α-oxoaldehydes by aminoguanidine under physiological conditions. International Congress Series, 2002, 1245, 513-515.	0.2	3
262	Methylglyoxal modification of LDL: proatherogenicity without oxidation opens new paths to prevent cardiovascular disease. Clinical Lipidology, 2011, 6, 631-634.	0.4	3
263	The inhibition of manganese superoxide dismutase by cacodylate. Inorganica Chimica Acta, 1982, 67, 75-78.	2.4	2
264	Inhibition of human leukaemia 60 cell growth by diethyl esterification of the glyoxalase II Inhibitor S-p-nitrobenzoxycarbonylglutathlone <i>in vitro</i> . Biochemical Society Transactions, 1993, 21, 159S-159S.	3.4	2
265	The assay of S-D-lactoylglutathione in biological systems. Biochemical Society Transactions, 1993, 21, 164S-164S.	3.4	2
266	Mechanism of the inhibition of growth of human leukaemia 60 cells by S-D-lactoylglutatathione. Biochemical Society Transactions, 1993, 21, 166S-166S.	3.4	2
267	Population genetics of human glyoxalases and the development of diabetic complications. Biochemical Society Transactions, 1993, 21, 172S-172S.	3.4	2
268	Synthesis of 14C-labelled aminoguanidine. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 179-184.	1.0	2
269	Synthesis of14C-labelled phenethyl isothiocyanate and the cysteine conjugate S-(N-phenethylthiocarbamoyl)cysteine and use under physiological conditions. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1069-1074.	1.0	2
270	Comparison of in vitro protein modification with advanced glycation endproduct (AGE) precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using mass spectrometry. International Congress Series, 2002, 1245, 353-354.	0.2	2

#	Article	IF	CITATIONS
271	Detection of 3-deoxyglucosone-derived AGE structures in vitro. International Congress Series, 2002, 1245, 239-242.	0.2	2
272	Removal of Free Advanced Glycation End Products by Hemodialysis. Annals of the New York Academy of Sciences, 2005, 1043, 922-922.	3.8	2
273	Severe thiamine deficiency complicated by weight loss protects against renal ischaemia-reperfusion injury in rats. CKJ: Clinical Kidney Journal, 2009, 2, 182-183.	2.9	2
274	Amino Acids Glycation Section. Amino Acids, 2012, 42, 1085-1086.	2.7	2
275	Special edition of Amino Acids of selected papers from the eleventh international symposium on the Maillard reaction, September 16–20, 2012. Amino Acids, 2014, 46, 259-259.	2.7	2
276	The Effect of Nitrone Spin Trapping Agents on Red Cell Glucose Metabolism. Free Radical Research Communications, 1985, 1, 111-117.	1.8	1
277	ELECTRON SPIN RESONANCE AND SPIN TRAPPING. , 1993, , 33-69.		1
278	Assay of early and advanced glycation adducts by enzymatic hydrolysis of proteins and HPLC of 6-aminoquinolylcarbonyl adducts. International Congress Series, 2002, 1245, 279-283.	0.2	1
279	Increased Plasma and Urinary Methylglyoxal-Derived Hydroimidazolone in Type 1 Diabetic Patients. Annals of the New York Academy of Sciences, 2005, 1043, 928-928.	3.8	1
280	Pro-Inflammatory Cytokine Synthesis by Human Monocytes Induced by Proteins Minimally-Modified by Methylglyoxal. , 2005, , 357-362.		1
281	New development in a blood-based diagnostic test for early-stage arthritis. Biomarkers in Medicine, 2015, 9, 943-945.	1.4	1
282	Glycation- and/or Polyol Pathway-Inducing Complications. , 2018, , 170-179.		1
283	Facile synthesis of (R)N-2-hydroxyacyl-L-cysteine derivatives: (R)N-2-hydroxyacyl transfer from enzymatically-synthesized (R)S-2-hydroxyacylglutathione derivatives to L-cysteine. Amino Acids, 1995, 9, 185-189.	2.7	1
284	Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathione derivatives. Biochemical Society Transactions, 1993, 21, 165S-165S.	3.4	0
285	Simple chromatographic methods for the purification of human red blood cell glyoxalase I and glyoxalase II to homogeneity. Biochemical Society Transactions, 1993, 21, 171S-171S.	3.4	Ο
286	In vitro kinetics of AGE formation with PD fluid resembles that of glucose degradation products rather than glucose. International Congress Series, 2002, 1245, 475-477.	0.2	0
287	Protein Glycation and Oxidation in Cola and Pasteurized Milk. Annals of the New York Academy of Sciences, 2005, 1043, 907-907.	3.8	0
288	Protein Glycation Marker Residues and Free Adducts of Cerebrospinal Fluid in Alzheimer's Disease and a Link to Cognitive Impairment. Annals of the New York Academy of Sciences, 2005, 1043, 914-914.	3.8	0

#	Article	IF	CITATIONS
289	Exogenous Methylglyoxal Induces Diabetes-like Microvascular Changes in Rats. Annals of the New York Academy of Sciences, 2005, 1043, 918-918.	3.8	0
290	Advanced Clycation End Product Excretion Rates by Peritoneal Dialysis in End-Stage Renal Disease. Annals of the New York Academy of Sciences, 2005, 1043, 921-921.	3.8	0
291	Factors influencing the development and effectiveness of biomarkers in rheumatoid arthritis and osteoarthritis. International Journal of Clinical Rheumatology, 2015, 10, 313-316.	0.3	0
292	192. INCREASED PROTEIN GLYCATION, OXIDATION AND NITRATION WITH INCREASING SEVERITY OF RHEUMATOID ARTHRITIS IN A CROSS-SECTIONAL STUDY ASSESSED BY ROBUST STABLE ISOTOPIC DILUTION ANALYSIS QUANTITATION. Rheumatology, 2017, 56, .	1.9	0
293	A Novel Therapeutic Approach in Triosephosphate Isomerase Deficiency Blood, 2006, 108, 3735-3735.	1.4	0
294	Thiamine in Diabetic Renal Disease: Dietary Insufficiency, Renal Washout, Antistress Gene Response, Therapeutic Supplements, Risk Predictor, and Link to Genetic Susceptibility. , 2011, , 93-104.		0
295	Inhibition of Glyoxalase I (EC4.4.1.5). Expert Opinion on Therapeutic Targets, 1997, 1, 203-206.	1.0	0